ProfileGDS5678 / 1456789_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 77% 77% 75% 73% 73% 77% 79% 74% 73% 75% 77% 75% 75% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.1839177
GSM967853U87-EV human glioblastoma xenograft - Control 25.2982977
GSM967854U87-EV human glioblastoma xenograft - Control 34.9904875
GSM967855U87-EV human glioblastoma xenograft - Control 44.7639473
GSM967856U87-EV human glioblastoma xenograft - Control 54.7607573
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.0404777
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.3392879
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.8366474
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.7658373
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.9754375
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.1740677
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.9599275
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.8876375
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.9761475